RxDoctor Payments Data

Chaim Gitelis, DO

Cardiovascular Disease · Brooklyn, NYNPI 1508086109

Payments from drug & device makers

$9,971in general payments, 2019–2025

Across 339 payments — averaging $29.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Boehringer Ingelheim$906
  • Johnson & Johnson$894
  • Merck$714
  • Pfizer$584
  • plus $4K from 22 others

What the payments were for

  • Food & beverage$9,87799%
  • Education$941%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,971 in reported general payments places this provider in the 80th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$4,160,798
Medicare patients
8,911
Services billed
76,275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban75$61,326
EntrestoSacubitril/Valsartan38$30,619
XareltoRivaroxaban25$19,735
FarxigaDapagliflozin Propanediol21$18,790
BrilintaTicagrelor28$17,990
Ranolazine ErRanolazine38$3,722
Metoprolol Succinate99$894
Ezetimibe17$870
Losartan Potassium87$759
Methenamine Hippurate13$702
Atorvastatin Calcium77$545
Furosemide33$515
Prasugrel Hcl11$443
Potassium Chloride14$437
Valsartan28$426

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$584$61,32675 claims
AstraZenecaFarxiga, Brilinta$1,719$36,78049 claims
NovartisEntresto$546$30,61938 claims
Johnson & JohnsonXarelto$894$19,73525 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$110$5616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →